Christopher Gerard insider trades: Amedisys (AMED) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
23 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 2, 2021 | AMED | ↓ Sell | 1,250 | $261.24 | $327K | Direct | Aug 4, 2021 (2d) |
| Jul 1, 2021 | AMED | ↓ Sell | 1,250 | $250.90 | $314K | Direct | Jul 6, 2021 (5d) |
| Jun 1, 2021 | AMED | ↓ Sell | 1,250 | $256.62 | $321K | Direct | Jun 3, 2021 (2d) |
| May 25, 2021 | AMED | ↓ Sell | 1,250 | $259.59 | $324K | Direct | May 27, 2021 (2d) |
| Jan 15, 2021 | AMED | ↓ Sell | 750 | $290.20 | $218K | Direct | Jan 20, 2021 (5d) |
| Dec 15, 2020 | AMED | ↓ Sell | 750 | $272.56 | $204K | Direct | Dec 17, 2020 (2d) |
| Nov 16, 2020 | AMED | ↓ Sell | 750 | $243.68 | $183K | Direct | Nov 18, 2020 (2d) |
| Oct 15, 2020 | AMED | ↓ Sell | 1,500 | $252.03 | $378K | Direct | Oct 19, 2020 (4d) |
| Sep 15, 2020 | AMED | ↓ Sell | 1,500 | $239.25 | $359K | Direct | Sep 17, 2020 (2d) |
| Aug 3, 2020 | AMED | ↓ Sell | 750 | $231.52 | $174K | Direct | Aug 5, 2020 (2d) |
| Jul 1, 2020 | AMED | ↓ Sell | 750 | $203.43 | $153K | Direct | Jul 6, 2020 (5d) |
| Jun 1, 2020 | AMED | ↓ Sell | 750 | $189.42 | $142K | Direct | Jun 3, 2020 (2d) |
| May 1, 2020 | AMED | ↓ Sell | 750 | $182.35 | $137K | Direct | May 5, 2020 (4d) |
| Apr 1, 2020 | AMED | ↓ Sell | 750 | $178.13 | $134K | Direct | Apr 3, 2020 (2d) |
| Mar 9, 2020 | AMED | ↓ Sell | 750 | $165.69 | $124K | Direct | Mar 11, 2020 (2d) |
| Feb 3, 2020 | AMED | ↓ Sell10b5-1 | 350 | $178.98 | $63K | Direct | Feb 5, 2020 (2d) |
| Jan 2, 2020 | AMED | ↓ Sell10b5-1 | 350 | $165.22 | $58K | Direct | Jan 6, 2020 (4d) |
| Dec 2, 2019 | AMED | ↓ Sell10b5-1 | 350 | $162.97 | $57K | Direct | Dec 4, 2019 (2d) |
| Nov 1, 2019 | AMED | ↓ Sell10b5-1 | 350 | $145.15 | $51K | Direct | Nov 5, 2019 (4d) |
| Oct 1, 2019 | AMED | ↓ Sell10b5-1 | 350 | $128.79 | $45K | Direct | Oct 3, 2019 (2d) |
| Sep 9, 2019 | AMED | ↓ Sell10b5-1 | 350 | $134.79 | $47K | Direct | Sep 11, 2019 (2d) |
| Mar 11, 2019 | AMED | ↓ Sell | 2,500 | $118.96 | $297K | Direct | Mar 13, 2019 (2d) |
| Nov 9, 2018 | AMED | ↓ Sell | 7,892 | $119.02 | $939K | Direct | Nov 14, 2018 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Christopher Gerard's insider trades
Christopher Gerard is President & COO at Amedisys (AMED). Since Nov 9, 2018, Christopher has reported no open-market purchases and 23 sales worth $5.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
6 sales (6% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include shares withheld for taxes (10 filings), grants and awards (5 filings), option exercises (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AMED insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.